Pladevall-Morera, D.; Castejón-Griñán, M.; Aguilera, P.; Gaardahl, K.; Ingham, A.; Brosnan-Cashman, J.A.; Meeker, A.K.; Lopez-Contreras, A.J.
ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors. Cancers 2022, 14, 1790.
https://doi.org/10.3390/cancers14071790
AMA Style
Pladevall-Morera D, Castejón-Griñán M, Aguilera P, Gaardahl K, Ingham A, Brosnan-Cashman JA, Meeker AK, Lopez-Contreras AJ.
ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors. Cancers. 2022; 14(7):1790.
https://doi.org/10.3390/cancers14071790
Chicago/Turabian Style
Pladevall-Morera, David, MarÃa Castejón-Griñán, Paula Aguilera, Karina Gaardahl, Andreas Ingham, Jacqueline A. Brosnan-Cashman, Alan K. Meeker, and Andres J. Lopez-Contreras.
2022. "ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors" Cancers 14, no. 7: 1790.
https://doi.org/10.3390/cancers14071790
APA Style
Pladevall-Morera, D., Castejón-Griñán, M., Aguilera, P., Gaardahl, K., Ingham, A., Brosnan-Cashman, J. A., Meeker, A. K., & Lopez-Contreras, A. J.
(2022). ATRX-Deficient High-Grade Glioma Cells Exhibit Increased Sensitivity to RTK and PDGFR Inhibitors. Cancers, 14(7), 1790.
https://doi.org/10.3390/cancers14071790